The Defense Health Agency (DHA) Small Business Innovation Research (SBIR) program funds biomedical and health-focused technologies that enhance medical readiness, clinical care delivery, force health protection, operational medicine, and military healthcare modernization. DHA SBIR topics are tightly aligned with real-world needs across trauma care, battlefield triage, far-forward telemedicine, infectious-disease diagnostics, wearable monitoring tools, physiological analytics, prosthetics, rehabilitation platforms, and US-based military hospital modernization. Because warfighter medical care must be rugged, fast, secure, interoperable, and clinically valid, DHA SBIR proposals must demonstrate both technical innovation and real clinical relevance. 

Priority research domains include traumatic injury stabilization, hemorrhage control, wound-care analytics, portable medical devices, physiological monitoring, rapid point-of-care diagnostics, digital health systems, AI-enabled triage, infection surveillance, behavioral health, medical logistics, pharmaceutical stability, biomanufacturing, patient movement optimization, and field-deployable rehabilitation. DHA strongly favors integrated clinical pathways, interoperable platforms, remote-care augmentation, and medical systems capable of deployment in austere environments, including shipboard, aviation, expeditionary, or humanitarian settings. 

Phase I DHA SBIR awards typically range from $150,000 to $225,000 and support early feasibility studies, pilot designs, early assay validation, physiology-based modeling, or preliminary field-care algorithms. Phase II awards—often between $1,000,000 and $1,600,000—support clinical prototyping, medical device refinement, usability and human-factor testing, FDA pathway planning, modeling for regulatory approval, field demonstrations, and assessments with Service medical units or military treatment facilities. DHA is unique among DoD SBIR components because medical regulatory strategy can be central to evaluation competitiveness, particularly for technologies entering FDA Class I, II, or III pathways. 

Eligibility mirrors standard SBIR requirements: U.S.-owned for-profit small businesses under 500 employees, the PI must be primarily employed by the small business, and at least 50% of research effort must be executed by the small business. Universities, medical schools, teaching hospitals, clinical research organizations, and federally funded laboratories may collaborate as subcontractors for assay development, tissue modeling, BSL laboratory work, UX evaluation, or clinical study development. Projects involving human subjects, diagnostic handling, pharmaceuticals, implanted devices, biospecimens, animal studies, or clinical simulation must meet strict DoD IRB, HIPAA, biosafety, and FDA regulatory requirements, including appropriate ethics approvals and controlled documentation. 

Competitive DHA SBIR proposals demonstrate: 
• clear clinical or operational relevance to military environments 
• manufacturability and ruggedization under austere conditions 
• alignment with triage workflows, telemedicine architectures, or medical logistics 
• a credible regulatory roadmap with FDA or device-exemption clarity 
• strong transition potential for Service medical units or field hospitals 
• dual-use commercialization in civilian trauma centers, EMS, VA health systems, biotech markets, or telehealth environments 

Example resources: 
DHA Research & SBIR: https://www.health.mil 
DoD SBIR Portal: https://www.dodsbirsttr.mil 

ScienceDocs Can Help 

ScienceDocs assists DHA SBIR and medical technology applicants with clinical proposal development, regulatory and FDA planning, usability and field-study design, medical narrative writing, milestone structuring, commercialization strategy, and technical editing. If your company plans to pursue a DHA SBIR submission or requires proposal development support, please begin the conversation at: https://www.sciencedocs.com/quotes